This site is intended only for healthcare professionals resident in the Republic of Ireland
Adapted from Fleischmann R et al 2017.1
XELJANZ in combination with methotrexate is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs. XELJANZ can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate.2
XELJANZ 5 mg BID and XELJANZ 11 mg prolonged-release once daily tablets are the only approved dosages for the treatment of RA, which should not be exceeded.2
Please refer to the XELJANZ Summary of Product Characteristics for full prescribing information
ACR = American College of Rheumatology; AE= Adverse Event; BID = Twice Daily; CI = Confidence interval; IR = Inadequate Response; MTX = Methotrexate; Q2W = Once every 2 weeks; RA = Rheumatoid Arthritis; SAE = Serious Adverse Event; SC = Subcutaneously
Learn more about the XELJANZ safety profile
Learn about dosing in RA
Find out more about how XELJANZ works
Legal Category: S1A
Further information is available upon request
Adverse events should be reported. Report an adverse event to your national reporting system (HPRA Pharmacovigilance)
Adverse events should also be reported to Pfizer Medical Information on 1800 633 363
Please sign in or register to gain access to information relating to Pfizer medicines and vaccines, medical conditions, patient materials and services.
This site is intended only for healthcare professionals resident in the Republic of Ireland. If you are a member of the public wishing to access information on a specific medicine, please visit https://www.medicines.ie
This website is brought to you by Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
Copyright © 2023 Pfizer Limited. All rights reserved.
The information contained on this site is reserved exclusively for healthcare professionals resident in the Republic of Ireland.
I confirm that I am a healthcare professional resident in the Republic of Ireland.*
If you select 'No', you will be redirected to Pfizer.ie, where you will be able to access information on Pfizer Healthcare Ireland.
PP-UNP-IRL-0176. January 2023